UK: Patents Court Considers New Approach To Scope Of Claims In Validity Context

Last Updated: 28 November 2017
Article by David Rose and Nina O'Sullivan

In August 2017, the Supreme Court issued its much-anticipated decision in Actavis v Lilly, substantially revising the approach to determining the scope of protection of patent claims in infringement cases, including the role to be played by the doctrine of equivalents. The Patents Court has now considered the Supreme Court's decision in a case concerning validity (in Mylan & Synthon v Yeda & Teva), suggesting, subject to a definitive further ruling from the Supreme Court on the issue, that the approach to assessing the scope of a claim for novelty and infringement purposes no longer remains the same. Consequently, whilst a claim could be infringed by a person doing exactly what the prior publication teaches, it could still be novel over that publication.

The decision also confirms the grant of Arrow declarations (discussed in our recent bulletin) will be heavily dependent upon the patentee's conduct; simply filing divisional applications and making statements of strength in relation to a patent portfolio will not be sufficient. More will be required to demonstrate the need for the certainty provided by an Arrow declaration, likely involving clear attempts to shield a patent from scrutiny. 


Wishing to clear the way to market for the launch of their 40 mg generic glatiramer acetate (GA) products, Mylan and Synthon sought revocation of Yeda's dosage regimen patent for the administration of GA therapy (EP (UK) 2 949 335 entitled "Low frequency glatiramer acetate therapy"). This is the latest battle in an ongoing dispute relating to GA (marketed by Teva, as exclusive licensee under the Patent, as Copaxone), with a further trial scheduled to take place in April 2018 relating to an improved process for its preparation.

Mylan/Synthon attacked Claims 1 and 3 on the grounds of lack of novelty, lack of inventive step and insufficiency (there was no dispute that the intended acts would infringe). They also sought Arrow declarations in light of further divisional applications filed by Teva.

Arnold J accepted the attack against Claims 1 and 3 of the Patent on the basis of obviousness: it was obvious to try 40mg TIW (three times weekly) and the skilled person would have had a fair expectation of success - in the sense that it would be efficacious compared to placebo and that it would be comparable in efficacy to 20mg QD, i.e., every day. Even if the inventions were not obvious, he would have found that Claim 3 was also invalid for want of technical contribution and insufficiency because the claim that 40mg TIW would be as efficacious, and more tolerable than, 20mg QD was speculative.  

Impact of Actavis v Lilly: claim interpretation

Of particular interest, however, is Arnold J's consideration of the Supreme Court's decision in Actavis v Lilly. First, he confirmed that, before considering the question of equivalents, the approach to the construction of patent claims should continue to be a purposive one. He rejected Teva/Yeda's argument that the 'normal interpretation' should now be a literal one, in the same manner as in a commercial contract, and without regard to the patentee's purpose.  In particular, he reiterated that commercial contracts are different to patents: a contract is a bilateral statement agreed between the contracting parties (a patent is a unilateral statement by the patentee) and they also contain promises by the contracting parties to each other (a patent describes and claims a legal monopoly). Whilst Lord Neuberger may have 'eschewed' the expression 'purposive construction' in Actavis v Lilly, he had clearly not intended to have meant that the purpose of the document, namely to describe and claim an invention, should no longer be considered.

Impact of Actavis v Lilly: Novelty

Before Actavis v Lilly, it had long been settled law that the scope of a claim was the same for both novelty and infringement (a patentee should not be able to claim a broad scope for the purposes of infringement, but a narrower one for the purposes of validity).

In Actavis v Lilly, the Supreme Court had decided that claims can be infringed on the basis of a doctrine of equivalents but did not discuss the impact on the assessment of novelty. Given his decision on obviousness, Arnold J's consideration of this issue is obiter and, indeed, he suggested that a further Supreme Court decision will be needed to obtain a definitive answer. That said, he agreed with Yeda/Teva that it is now no longer the law that a claim lacks novelty if the prior publication disclosed subject matter which, if performed, would necessarily infringe the claim. Instead, a claim will only lack novelty if the prior art publication disclosed subject matter which fell within the claim on its proper interpretation. It is not sufficient if the subject-matter would infringe the claim applying the doctrine of equivalents. 

No Arrow declaration

Given the finding of obviousness, Mylan and Synthon sought Arrow declarations relying on the Court of Appeal's decision in the Humira litigation. The Patent stems from a divisional and Teva has filed two further pending divisional applications. However, clearly the circumstances before the Court were not of the same magnitude as those seen in relation to Abbvie; indeed, Arnold J stressed that the existence of pending divisional applications is not enough, on its own, to justify the making of an Arrow declaration. He also rejected the argument that Teva/Yeda had sought to shield the Patent's subject matter from scrutiny by the UK and Dutch courts, and also by the EPO Board of Appeal, and there was also nothing in the argument that Teva had made public statements that it would enforce its patent portfolio. In summary, he concluded, an Arrow declaration would provide no greater commercial certainty than the judgment of the court on validity of the Patent (the same point applying in respect of the alleged spin-off value of the Arrow declaration).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions